WO2002066477A3 - Composes - Google Patents

Composes Download PDF

Info

Publication number
WO2002066477A3
WO2002066477A3 PCT/GB2002/000634 GB0200634W WO02066477A3 WO 2002066477 A3 WO2002066477 A3 WO 2002066477A3 GB 0200634 W GB0200634 W GB 0200634W WO 02066477 A3 WO02066477 A3 WO 02066477A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
compound
relates
present
imidazopyridines
Prior art date
Application number
PCT/GB2002/000634
Other languages
English (en)
Other versions
WO2002066477A2 (fr
Inventor
Alexander Graham Dossetter
Peter Kenny
Darren Mckerrecher
Michael Wardleworth
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Alexander Graham Dossetter
Peter Kenny
Darren Mckerrecher
Michael Wardleworth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Alexander Graham Dossetter, Peter Kenny, Darren Mckerrecher, Michael Wardleworth filed Critical Astrazeneca Ab
Priority to AU2002229976A priority Critical patent/AU2002229976A1/en
Publication of WO2002066477A2 publication Critical patent/WO2002066477A2/fr
Publication of WO2002066477A3 publication Critical patent/WO2002066477A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (I), dans laquelle R1, R2 et R3 représentent des éléments définis dans la partie descriptive de la présente demande et le noyau A est éventuellement davantage substitué. Ces composés sont des antagonistes de l'activité de l'hormone de libération de la gonadotrophine (GnRH). L'invention concerne également des préparations pharmaceutiques, l'utilisation d'un composé de la présente invention dans la fabrication d'un médicament, une méthode de traitement thérapeutique qui utilise ce composé et des procédés destinés à la production de ces composés.
PCT/GB2002/000634 2001-02-20 2002-02-15 Composes WO2002066477A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002229976A AU2002229976A1 (en) 2001-02-20 2002-02-15 Imidazopyridines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100567A SE0100567D0 (sv) 2001-02-20 2001-02-20 Compounds
SE0100567-7 2001-02-20

Publications (2)

Publication Number Publication Date
WO2002066477A2 WO2002066477A2 (fr) 2002-08-29
WO2002066477A3 true WO2002066477A3 (fr) 2002-10-17

Family

ID=20283057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000634 WO2002066477A2 (fr) 2001-02-20 2002-02-15 Composes

Country Status (3)

Country Link
AU (1) AU2002229976A1 (fr)
SE (1) SE0100567D0 (fr)
WO (1) WO2002066477A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10246890A1 (de) * 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
DE10247271A1 (de) * 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
CA2544213A1 (fr) 2003-10-28 2005-05-19 Sepracor Inc. Anxiolytiques d'imidazo[1,2-a]pyridine
GB0403781D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical compounds
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (fr) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines utilisees pour traiter l'hepatite c
EP1961745A1 (fr) 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Compose heterocyclique bicyclique
CN101410397A (zh) * 2006-03-31 2009-04-15 诺瓦提斯公司 有机化合物
WO2008027812A2 (fr) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Dérivés d'imidazopyridine et d'imidazopyrimidine
JP5159630B2 (ja) 2006-09-13 2013-03-06 協和発酵キリン株式会社 縮環複素環誘導体
WO2008078091A1 (fr) 2006-12-22 2008-07-03 Astex Therapeutics Limited Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr
WO2008078100A2 (fr) 2006-12-22 2008-07-03 Astex Therapeutics Limited Nouveaux composés
EP1964840A1 (fr) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines et leur utilisation en tant que produits pharmaceutiques
CN103214482B (zh) 2007-04-03 2016-06-29 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
CA2703649A1 (fr) * 2007-10-24 2009-04-30 Shigeyuki Tanifuji Nouveau compose possedant une affinite vis-a-vis d'une substance amyloide
US8497278B2 (en) * 2008-05-19 2013-07-30 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201242965A (en) 2011-02-01 2012-11-01 Kyowa Hakko Kirin Co Ltd Ring-fused heterocyclic derivative
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CN104619707A (zh) 2012-07-31 2015-05-13 协和发酵麒麟株式会社 稠环杂环化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MD3394033T2 (ro) 2015-12-22 2021-04-30 Incyte Corp Compuși heterociclici ca imunomodulatori
US9926316B2 (en) * 2016-03-03 2018-03-27 The Cleveland Clinic Foundation Antitumor derivatives for differentiation therapy
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (fr) 2016-05-26 2017-11-30 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
LT3472167T (lt) 2016-06-20 2022-11-10 Incyte Corporation Heterocikliniai junginiai kaip imunomoduliatoriai
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102641030B1 (ko) 2016-12-22 2024-02-29 인사이트 코포레이션 Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
BR112019012993A2 (pt) 2016-12-22 2019-12-03 Incyte Corp derivados de benzo-oxazol como imunomoduladores
LT3774791T (lt) 2018-03-30 2023-04-11 Incyte Corporation Hererocikliniai junginiai kaip imunomoduliatoriai
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
WO2021030162A1 (fr) 2019-08-09 2021-02-18 Incyte Corporation Sels d'un inhibiteur de pd-1/pd-l1
KR20220075382A (ko) 2019-09-30 2022-06-08 인사이트 코포레이션 면역조절제로서의 피리도[3,2-d]피리미딘 화합물
MX2022005651A (es) 2019-11-11 2022-07-27 Incyte Corp Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
WO2022099018A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Procédé de préparation d'un inhibiteur de pd-1/pd-l1
AU2021373044A1 (en) 2020-11-06 2023-06-08 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
WO2022099075A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Forme cristalline d'un inhibiteur pd-1/pd-l1
CN113666926A (zh) * 2021-09-08 2021-11-19 桂林理工大学 一种便捷的2-苯基咪唑[1,2-a]吡啶与查尔酮的Michal加成反应

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019953A2 (fr) * 1995-11-28 1997-06-05 Asta Medica Aktiengesellschaft Nouveaux antagonistes a efficacite amelioree de l'hormone liberant l'hormone luteinisante
WO1998003505A2 (fr) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Composes heterocycliques, leur production et leur utilisation
WO1999020223A2 (fr) * 1997-10-20 1999-04-29 Novo Nordisk A/S Antagonistes de l'hormone luteinisante utiles pour le traitement de carences oestrogeniques ou utilises en tant que contraceptif
WO1999041251A1 (fr) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonistes de l'hormone de liberation de la gonadotrophine
WO1999041252A1 (fr) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonistes de l'hormone de liberation de la gonadotrophine
WO2001055119A2 (fr) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Antagonistes du recepteur de la gonadoliberine et methodes associees
WO2001083481A1 (fr) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazopyridine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019953A2 (fr) * 1995-11-28 1997-06-05 Asta Medica Aktiengesellschaft Nouveaux antagonistes a efficacite amelioree de l'hormone liberant l'hormone luteinisante
WO1998003505A2 (fr) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Composes heterocycliques, leur production et leur utilisation
WO1999020223A2 (fr) * 1997-10-20 1999-04-29 Novo Nordisk A/S Antagonistes de l'hormone luteinisante utiles pour le traitement de carences oestrogeniques ou utilises en tant que contraceptif
WO1999041251A1 (fr) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonistes de l'hormone de liberation de la gonadotrophine
WO1999041252A1 (fr) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonistes de l'hormone de liberation de la gonadotrophine
WO2001055119A2 (fr) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Antagonistes du recepteur de la gonadoliberine et methodes associees
WO2001083481A1 (fr) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazopyridine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAMINSKI J J ET AL: "JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 28, no. 7, 1985, pages 876 - 892, XP002094814, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Also Published As

Publication number Publication date
AU2002229976A1 (en) 2002-09-04
WO2002066477A2 (fr) 2002-08-29
SE0100567D0 (sv) 2001-02-20

Similar Documents

Publication Publication Date Title
WO2002066477A3 (fr) Composes
SE0100568D0 (sv) Compounds
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
WO2003000343A3 (fr) Administration d'inhibiteurs de phosphodiesterase destinee au traitement de l'ejaculation precoce
WO2003048164A3 (fr) Antagonistes du recepteur a2a de l'adenosine
NZ514574A (en) Novel method of treatment
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
WO2005077950A3 (fr) Composes
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2004037789A8 (fr) Derives de methylene uree
WO2002065979A3 (fr) Nouveaux composes de pyrimidine
MXPA04003192A (es) Sales de acido succinico de 5, 7, 14-triazatetraciclo ?10.3.1.02,11.04,9? -hexadeca-2(11), 3, 5, 7, 9-pentaeno y composiciones farmacetucias de las mismas.
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
WO2005016867A3 (fr) Composes chimiques
SE0100566D0 (sv) Compounds
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2004032826A3 (fr) Procede de preparation de comprimes, de capsules ou d'autres formes solides de dosage de tannate
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
SE0102440D0 (sv) New compound
MY153713A (en) A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate
MXPA04000779A (es) 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades.
WO2003047505A3 (fr) Agents toxiques de topoisomerase
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
WO2002092565A3 (fr) Composes
HK1075894A1 (en) Prucalopride-n-oxide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP